Earnings OutlookThe company's earnings prospects for 2025 were disappointing, and the share price reacted negatively.
Generics ImpactThe Crop Science business is facing a broader-than-expected generics impact, affecting the company's overall performance.
Litigation ConcernsOngoing litigation related to glyphosate is creating uncertainty for investors, with 67,000 cases still unsettled.